Genmab A/S (NASDAQ:GMAB) Receives $45.20 Average Price Target from Analysts
Shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have issued a buy recommendation […]
More Stories
Seasonal Promotions That Can Help Increase Sales at Auto Repair Shops
Car repair shops frequently experience varying levels of demand at different times of the year. Implementing special promotions during specific...
Brokerages Set Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) PT at $64.67
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten ratings...
Viasat, Inc. (NASDAQ:VSAT) Given Average Rating of “Hold” by Brokerages
Viasat, Inc. (NASDAQ:VSAT – Get Free Report) has earned a consensus rating of “Hold” from the six ratings firms that...
Jamf Holding Corp. (NASDAQ:JAMF) Receives Consensus Recommendation of “N/A” from Brokerages
Shares of Jamf Holding Corp. (NASDAQ:JAMF – Get Free Report) have earned an average rating of “N/A” from the zero...
RAPT Therapeutics Announces License Agreement and Private Placement
RAPT Therapeutics, Inc. recently disclosed key developments in an 8-K filing with the Securities and Exchange Commission. The document, dated...
OptimizeRx Corporation Announces CEO Transition and Interim Appointment
OptimizeRx Corporation, listed on the Nasdaq under the symbol OPRX, recently disclosed in an 8-K filing to the Securities and...